Elekta EKTA B
This picture changes. Follow Elekta free — email when the signal or risk changes + a Sunday weekly brief.
Follow Elekta freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 19 Jul 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Maintain existing position; avoid adding exposure until order intake and China effects can be assessed in upcoming reports.
Hold: cost savings and margin support remain intact, but heightened China risk and weak order intake warrant waiting for Q1/Q2 evidence of stabilisation.
Market sentiment
1/10
↓
Trend: Declining
Sentiment has deteriorated further after the China VBP news and rising short interest; uncertainty around China exposure now dominates.
Risk assessment
9/10
Dilution:
Low
Positive cash flow; no equity raise indicated
Jurisdiction:
Low
Sweden/US core; some China exposure
Execution:
Medium
US rollout and restructuring must deliver
Recent changes
- The report showed revenue of 4,762 MSEK (-8%) and order intake -15% in constant currency (below expectations), while adjusted EBIT improved to 902 MSEK (18.9%) and full-year free cash flow rose to SEK 1.39bn.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Elekta is a Swedish medtech company selling radiotherapy systems (linear accelerators), radiosurgery (Gamma Knife), and oncology software. The company recently received FDA 510(k) clearance for Elekta Evo in the US and is executing a cost-saving program to improve margins.
Sector:
Radiotherapy medtech and oncology software
Type:
Other
Next report
27 Aug 2026
Q1
Catalysts
27 Aug 2026
Q1 2026/27 report
High
Q3 2026
Evo rollout in the US
High
Horizon:
Bull case
Annual cost savings above SEK 500 million and improved cash flow provide margin support once order intake stabilises.
Bear case
Chinese VBP procurement risks sharp price cuts on 10–15 % of sales and has already lifted short interest to 14.4 %.
Signal rationale (informational)
Hold: cost savings and margin support remain intact, but heightened China risk and weak order intake warrant waiting for Q1/Q2 evidence of stabilisation.
Recent news
- On 14 July 2026 China announced inclusion of major medical equipment in national VBP procurement. Elekta assesses limited impact on its China growth plans, yet the share fell 8 % the same day and short interest rose to 14.4 % of capital.
Price & valuation
Last close
SEK 52.45
1 week
+6.3 %
3 months
-6.8 %
12 months
+10.4 %
From 52w high
-17.1 %
From 52w low
+23.8 %
Exchange
Stockholm
Sector
Radiotherapy medtech and oncology software
This picture changes. Follow Elekta free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.